HKSE · 3839.HK
CPBIO Holding Company Limited
HK$7.81+HK$0.19 (+2.43%)
CPBIO Holding Company Limited’s quoted price sits in the upper half of its reported 52-week range, 21.08% below the high.
Loading market information…
HKSE · 0950.HK · HKD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 07:47 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Lee's Pharmaceutical Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 46.72% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Lee's Pharmaceutical Holdings Limited’s forward annual dividend is HK$0.07 per share, paid semi-annual. The forward yield is 6.64% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Lee's Pharmaceutical Holdings Limited’s next earnings report is currently expected on Mar 30, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Lee's Pharmaceutical Holdings Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It focuses on various disease areas, such as cardiovascular, woman's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. It operates in Proprietary and Generic Products; and Licensed-In Products segments. The Proprietary and Generic Products segment manufactures and sells Nadroparin Calcium injection and Livaracine to treat blood clots and deep vein thrombosis; Yallaferon for viral infection; Slounase for hemostasis; Socazolimab Injection for Recurrent or metastatic cervical cancer; Treprostinil injection for pulmonary arterial hypertension; fondaparinux sodium injection for deep vein thrombosis; and Sodium Phenylbutyrate Granules to treat urea cycle disorders; Apremilast Tablets for Plaque psoriasis; and Azilsartan Tablets for hypertension. The Licensed-In Products segment offers Sancuso for chemotherapy induced nausea and vomiting; Bredinin to treat Immunosuppression in renal transplantation; Centraxal Plus for acute otitis media with tympanostomy tubes; and Ferplex to treat iron deficiency anemia. This segment also offers Intrarosa for vulvovaginal atrophy; Adasuve for agitation associated with schizophrenia or bipolar I disorder in adults; Mictonorm for urinary incontinence; Natulan for Stage III and IV Hodgkin's disease; Lutrate for Prostate cancer; Nitric Oxide for Inhalation for Hypoxic respiratory failure associated with pulmonary hypertension; Omacor to treat Omega-3-acid ethyl esters; Zanidip for hypertension; Readyfusor for post-operative pain management; Teglutik to treat Amyotrophic lateral sclerosis; Trittico for insomnia/depression; Dicoflor and VSL#3 for probiotics; and Zingo for topical local analgesics. The company was founded in 1994 and is headquartered in Sha Tin, Hong Kong.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:19 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2022 |
|---|
| Mar 30, 2023 |
| HK$0.01 |
| HK$256.15M-78.16% vs estimate |
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$7.81+HK$0.19 (+2.43%)
CPBIO Holding Company Limited’s quoted price sits in the upper half of its reported 52-week range, 21.08% below the high.
HK$2.70+HK$0.01 (+0.37%)
Jilin Province Huinan Changlong Bio-pharmacy Company Limited’s quoted price sits in the upper half of its reported 52-week range, 10.0% below the high.
HK$1.83+HK$0.08 (+4.57%)
Arrail Group Limited’s quoted price sits in the lower half of its reported 52-week range, 40.0% below the high.
CN¥7.40+CN¥0.24 (+3.35%)
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 21.36% below the high.
HK$0.90HK$0.00 (0.0%)
Tian An Medicare Limited’s quoted price sits in the lower half of its reported 52-week range, 34.19% below the high.
HK$2.50+HK$0.02 (+0.6%)
Pak Fah Yeow International Limited’s quoted price sits in the upper half of its reported 52-week range, 8.42% below the high.
HK$2.20HK$0.00 (0.0%)
EuroEyes International Eye Clinic Limited’s quoted price sits in the lower half of its reported 52-week range, 34.33% below the high.
HK$4.00+HK$0.10 (+2.56%)
Gaush Meditech Ltd’s quoted price sits in the lower half of its reported 52-week range, 59.96% below the high.
